GlobalRPH - Lung Cancer News

Medical News

< back to feeds
Lung Cancer News
ASCO Releases Updated Treatment Guidelines For Patients With Stage 4 Non-Small Cell Lung Cancer New recommendations on the use of chemotherapy to treat patients with stage 4 non-small cell lung cancer (NSCLC) were issued today by the American Society of Clinical Oncology (ASCO). The evidence-based clinical practice guideline indicates a patient's physical age should not determine the cancer treatment he/she is given. ...more	17 Nov 2009
Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Of Picoplatin In Small Cell Lung Cancer Did Not Meet Primary Endpoint Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) announced that its pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in the second-line treatment of small cell lung cancer (SCLC) did not meet its primary endpoint of overall survival. The analysis, based on 320 evaluable events (patient deaths), showed a hazard ratio of 0.82 with a p value of 0.089. "We are disappointed that the trial did not meet the primary endpoint. ...more	17 Nov 2009
Scientific Presentations At 2009 ASTRO Meeting Highlight RapidArc(R) Radiotherapy Technology From Varian Medical Systems Clinicians using RapidArc® radiotherapy technology for fast, precise, non-invasive cancer treatments have found that they are able to substantially reduce scatter dose to surrounding healthy tissues, according to several presentations and posters presented this week at the annual meeting of the American Society for Radiation Oncology (ASTRO) in Chicago. ...more	13 Nov 2009
Potential New Lung Cancer Drug Shrank Tumors In Mice Researchers in the UK working with a new experimental drug for lung cancer showed that it eliminated small cell lung cancer tumors in 50 per cent of mice and also stopped tumors from growing and becoming resistant to treatment. The researchers now plan to do clinical trials to test whether the drug might be able to help people with small cell lung cancer, which can't be treated with surgery because it spreads so fast. ...more	12 Nov 2009
Dust Control Research Leads To A NIOSH Grant To Facilitate Adoption Of Hazard Controls In the construction industry, respiratory disease, often leading to disability or an increased risk of cancer, is a major public health concern. Studies led by Deborah Young-Corbett, a faculty member in Virginia Tech's School of Construction, have shown that specific types of sanding tools are highly effective in reducing the dust that causes these health hazards, yet the industry's usage of the available technology remains very low. ...more	12 Nov 2009
Drug Shrinks Lung Cancer Tumors In Mice A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published in the journal Cancer Research. In the animals, the drug also stopped lung cancer tumours from growing and becoming resistant to treatment. The authors of the research, from Imperial College London, are now planning to take the drug into clinical trials, to establish whether it could offer hope to patients with an inoperable form of lung cancer. ...more	11 Nov 2009
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results At CTOS Annual Meeting Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th. ...more	10 Nov 2009
PET Imaging Response A Prognostic Factor After Thoracic Radiation Therapy For Lung Cancer A rapid decline in metabolic activity on a PET scan after radiation therapy for non-small cell lung cancer is correlated with good local tumor control, according to a study presented by researchers at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting. In addition, the researchers also found that the higher the metabolic activity and tumor size on a PET scan before treatment, the more likely a patient is to die from lung cancer. ...more	10 Nov 2009
Biomoda Honors Veterans With Pledge To Lower Rate Of Lung Cancer Biomoda, Inc. (OTCBB: BMOD) President John Cousins called upon governors in all 50 states to proclaim November "Lung Cancer Awareness Month" on behalf of veterans and their families and pledged to continue the company's focus on veterans in the research, development and commercialization of diagnostic technology for detection of early-stage lung cancer. "America can truly honor its 25 million veterans by making a commitment to fight lung cancer. ...more	10 Nov 2009
New Treatment Option Emerging For Some With Early Stage Lung Cancer Patients with early stage, non-small cell lung cancer who are not able to undergo surgery, now have a highly effective treatment option. Physicians say that option, radical stereotactic radiosurgery performed with CyberKnife, leads to a 100 percent overall survival after three years in patients with good lung function before treatment. These are the results of a study presented at the annual CHEST meeting in San Diego. ...more	04 Nov 2009
In Non-Small Cell Lung Cancer PET Imaging Before Radiation Not Ideal For Determining Boost Radiation Doses Positron emission tomography (PET) imaging of non-small cell lung cancer prior to receiving radiation therapy should not be the basis for determining areas that may benefit from higher doses of radiation, according to research presented by investigators at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting (Abstract #2583/B-186). ...more	04 Nov 2009
NHS Still Failing Lung Cancer Patients Say Experts, UK The NHS is still failing lung cancer patients, according to the results of the first national review of lung cancer services, published this Monday.1 Despite headway in UK lung cancer prevention, disease awareness and screening, key areas such as diagnosis, treatment rates and access to specialists are still 'woefully inadequate' say the UK's leading lung cancer experts. ...more	04 Nov 2009
The Benefits And Risks Of Preventative Brain Radiation For Lung Cancer Patients A new study is taking a closer look at the benefits versus risks for lung cancer patients to undergo preventative brain radiation therapy as a means to stop cancer from spreading to the brain. Study results show that while preventative brain radiation for patients with non-small cell lung cancer - the most common form of lung cancer - does reduce the chance of developing brain metastases, it impacts some short-term and long-term memory. ...more	03 Nov 2009
Side Effects Of Stereotactic Body Radiation Therapy In Lung Cancer Patients Significantly Increased By Obesity Obesity, not the amount of radiation given, is the greatest factor in whether early-stage lung cancer patients develop chest wall pain after receiving stereotactic body radiation therapy to the chest wall, with obese patients being more than twice as likely to develop chronic pain compared to those who have less body weight, according to a first-of-its-kind study presented Tuesday, November 3, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO). ...more	03 Nov 2009
Noninvasive, Effective Treatment For Frail Patients With Early-Stage Lung Cancer Offered By Stereotactic Radiotherapy Stereotactic body radiation therapy (SBRT) should be considered a new standard of care for early-stage lung cancer treatment in patients with co-existing medical problems, according to results from a national clinical trial led by UT Southwestern Medical Center physicians. ...more	03 Nov 2009
What Are The Real Benefits Versus Risks Of Preventative Brain Radiation For Patients With Non-small Cell Lung Cancer? Patients with non-small cell lung cancer treated with preventative brain radiation (called prophylactic cranial irradiation or PCI), significantly decrease their risk of developing brain metastases (cancer spread in the brain) by more than 50 percent (from 18 percent to 8 percent), compared to th ...more	03 Nov 2009
Study Spotlights Efficacy Of Questionnaire To Identify Patients At High Risk For Lung Cancer A study featured in the November issue of the Journal of Thoracic Oncology confirms the success of a simple questionnaire designed to identify patients at high risk of lung cancer. Initiated in 2001, the current study confirmed 18 cases of cancer of the original 430 patients who qualified as high risk after completing a five-minute questionnaire. The study was conducted in primary care physician offices among patients seeking care for general health issues. ...more	02 Nov 2009
Health Care Disparity Revealed By Intervals Between Lung Cancer Diagnosis And Treatment Research published in the November 2009 issue of the Journal of Thoracic Oncology has found that intervals between lung cancer suspicion, diagnosis and treatment may be attributed to health care system discrepancies. To gain better insight on this topic, researchers studied the timing of lung cancer diagnosis and treatment at a U.S. medical center providing care to a diverse patient population within two different hospital systems. David E. ...more	02 Nov 2009
AstraZeneca Withdraws Its Marketing Authorisation Application For Zactima (vandetinib), Europe The European Medicines Agency has been formally notified by AstraZeneca of its decision to withdraw its application for a centralised marketing authorisation for the medicine Zactima (vandetinib), 100 mg film-coated tablets. Zactima was expected to be used in combination with chemotherapy, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received prior anticancer therapy. ...more	31 Oct 2009
Drug-Radiation Combo Used To Eradicate Lung Cancer In Mouse Model Researchers at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation. ...more	31 Oct 2009
Pages of Results: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 [Next] [Last Page]
Lung Cancer News courtesy of Medical News Today	back to top

Medical News

Looking for a Job?

Career Center

Popular Tools

Disclaimer Contact Us Privacy Policy Website Search	We comply with the HONcode standard for health trustworthy information: Verify here. Copyright © 2007 GlobalRPh Inc.